程序性死亡蛋白 1 抗体治疗 Epstein-Barr 病毒相关肝内胆管细胞癌患者的疗效。
Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
机构信息
VIP Region, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, PR China.
Department of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, PR China.
出版信息
Eur J Cancer. 2023 Nov;194:113337. doi: 10.1016/j.ejca.2023.113337. Epub 2023 Sep 9.
AIM
Epstein-Barr virus-associated intrahepatic cholangiocarcinoma (EBVaICC) has a distinct genomic profile and increased CD3 and CD8 T cells infiltration. However, the efficacy of immunotherapy in EBVaICC remains largely unknown. This study aimed to assess the efficacy of programmed cell death protein 1 (PD-1) antibody therapy in EBVaICC.
METHODS
Patients with metastatic biliary tract cancer (BTC) diagnosed at Sun Yat-sen University Cancer Center from January 2016 to December 2021 were identified. In situ hybridisation was performed to detect EBV. Overall survival (OS) and progression-free survival (PFS) were measured.
RESULTS
A total of 698 patients with metastatic BTC were identified, of whom 39 (5.6%) had EBVaICC. Among the 136 patients who were not administered PD-1 antibody, the OS was similar between patients with EBVaICC and EBV-negative ICC (median OS 12.5 versus 9.5 months, respectively; P = 0.692). For the 205 patients who were administered PD-1 antibody, patients with EBVaICC had significantly longer OS than patients with EBV-negative ICC (median OS 24.9 versus 11.9 months, respectively; P = 0.004). Seventeen patients with EBVaICC were administered PD-1 antibody. Eight patients (47%) achieved a partial response, and 17 patients achieved disease control. The median PFS was 17.5 months.
CONCLUSIONS
This study identified a clinically actionable subset of patients with EBVaICC with a promising response to the PD-1 antibody.
目的
Epstein-Barr 病毒相关的肝内胆管癌（EBVaICC）具有独特的基因组特征和增加的 CD3 和 CD8 T 细胞浸润。然而，免疫疗法在 EBVaICC 中的疗效在很大程度上仍然未知。本研究旨在评估程序性细胞死亡蛋白 1（PD-1）抗体治疗在 EBVaICC 中的疗效。
方法
本研究回顾性分析了中山大学肿瘤防治中心 2016 年 1 月至 2021 年 12 月期间诊断为转移性胆道癌（BTC）的患者。采用原位杂交法检测 EBV。测量总生存期（OS）和无进展生存期（PFS）。
结果
共纳入 698 例转移性 BTC 患者，其中 39 例（5.6%）为 EBVaICC。在未接受 PD-1 抗体治疗的 136 例患者中，EBVaICC 患者与 EBV 阴性 ICC 患者的 OS 相似（中位 OS 分别为 12.5 个月和 9.5 个月；P=0.692）。在接受 PD-1 抗体治疗的 205 例患者中，EBVaICC 患者的 OS 明显长于 EBV 阴性 ICC 患者（中位 OS 分别为 24.9 个月和 11.9 个月；P=0.004）。17 例 EBVaICC 患者接受了 PD-1 抗体治疗。8 例患者（47%）获得部分缓解，17 例患者获得疾病控制。中位 PFS 为 17.5 个月。
结论
本研究确定了一个具有临床可操作性的 EBVaICC 亚组患者，对 PD-1 抗体反应良好。
Zotero 插件